What is Retatrutide?
Retatrutide is a triple-agonist research peptide that activates the GLP-1, GIP, and glucagon receptors. It is studied in preclinical metabolic-pathway models for its combined incretin and glucagonergic effects.
Retatrutide is a next-generation research peptide investigated for its triple receptor agonism — it activates the GLP-1, GIP, and glucagon receptors simultaneously.
Why this matters in research:
- The GLP-1 axis influences insulin secretion and satiety signaling.
- The GIP axis is the second major incretin pathway.
- The glucagon axis contributes to energy expenditure and lipolysis in preclinical models.
By engaging all three, Retatrutide enables researchers to study a more complete picture of incretin- and glucagon-driven metabolic regulation than single- or dual-agonist compounds allow.
Retatrutide is supplied strictly for in-vitro and preclinical laboratory investigation. It is not approved for human therapeutic use. See the Metabolic pathway for related GLP-1 / GIP / glucagon research compounds.
// Related research pathways